| Age at Diagnosis-year (range) |
51.3 (18.5–83.7) |
55.8 (20.6–78.2) |
49.1 (18.5–83.7) |
0.07 |
| Gender-male-no. (%) |
104 (62.3) |
18 (56.3) |
86 (63.7) |
0.54 |
| Median Length of Stay-days (range) |
6 (2–164) |
14 (3–164) |
5 (2–97) |
<0.001 |
| Race |
| Caucasian-no. (%) |
128 (76.6) |
25 (78.1) |
103 (76.3) |
0.45 |
| Asian-no. (%) |
20 (12) |
2 (6.3) |
18 (13.3) |
|
| Black-no. (%) |
15 (9) |
4 (12.5) |
11 (8.1) |
|
| Latino/Hispanic-no. (%) |
2 (1.2) |
0 (0) |
2 (1.5) |
|
| Other-no. (%) |
2 (1.2) |
1 (3.1) |
1 (0.7) |
|
| Service |
| Leukemia-no. (%) |
41 (24.6) |
7 (21.9) |
34 (25.2) |
0.82 |
| Lymphoma-no. (%) |
126 (75.4) |
25 (78.1) |
101 (74.8) |
|
| Factors effecting methotrexate clearance |
| Presence of Edema-no. (%) |
20 (12) |
8 (25) |
12 (8.9) |
0.029 |
| Presence of Ascites/Pleural Effusion-no. (%) |
13 (7.8) |
8 (25) |
5 (3.7) |
0.001 |
| Presence of Fluid Retention-no. (%) |
27 (16.2) |
11 (34.4) |
16 (11.9) |
0.006 |
| Use of Concomitant Nephrotoxic Agents-no. (%) |
40 (24) |
13 (40.6) |
27 (20) |
0.021 |
| Drug Interactions-no. (%) |
100 (59.9) |
23 (71.9) |
77 (57) |
0.16 |
| Urine pH < 7 |
47 (28.1) |
8 (25) |
39 (28.9) |
0.83 |
| Baseline Kidney Impairment |
57 (34.1) |
11 (34.4) |
46 (34.1) |
1.00 |
| Baseline median creatinine-g/dL |
0.8 (0.3–1.5) |
0.7 (0.4–1.3) |
0.8 (0.3–1.5) |
0.17 |
| Baseline median creatinine clearance-mL/min |
107.9 (46.2–279) |
114.3 (49.7–180.5) |
106.3 (46.2–279) |
0.69 |
| Dosing category |
| Low-high dose methotrexate (1–2.9 g/m2)-no (%) |
46 (27.5) |
11 (34.4) |
35 (25.9) |
0.40 |
| Intermediate-high dose methotrexate (3–5.9 g/m2)-no (%) |
100 (59.9) |
19 (59.4) |
81 (60) |
|
| High-high dose methotrexate (≥6 g/m2)-no (%) |
21 (12.6) |
2 (6.3) |
19 (14.1) |
|
